Bioinformatics company ArteraAI has recently released data that validates the first-ever predictive AI biomarker for assessing the benefits of androgen deprivation therapy (ADT) in prostate cancer. ADT is a treatment often used in combination with radiotherapy, but it is associated with known adverse effects.

The newly developed biomarker aids in the identification of patients that are more likely to benefit from androgen deprivation therapy (ADT), facilitating personalized treatment strategies. The study employed deep-learning techniques and analyzed histopathology image data from over 5,000 patients participating in five Phase III randomized trials. This milestone study involved patients from multiple centers in the US and Canada, representing a significant advancement in the field of prostate cancer treatment.

California-based Artera is a precision medicine company that is working on AI tests with the aim of customizing treatment options for patients suffering from cancer. The company’s flagship test is a test to identify patients that will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. The test is clinically available through a single CLIA-certified laboratory in Jacksonville, Florida, and costs USD 3,873.